Gaïa Paris

Gaïa Paris is a SAMHSA-registered addiction-treatment facility located at DE. The specific care levels offered by Gaïa Paris should be confirmed directly with the admissions team. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Gaïa Paris

Level-of-care documentation: Care-level specifics for Gaïa Paris are not well-documented in the public SAMHSA record; a direct conversation with the admissions team is the reliable way to confirm what the facility actually provides. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Payment and insurance specifics for Gaïa Paris are not fully documented in the SAMHSA registry — a direct admissions conversation is the reliable way to confirm what forms of payment are accepted and at what network-contract level. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Before you call

Operational admission checklist for Gaïa Paris: (a) clinical assessment with documented ASAM 4e level-of-care recommendation; (b) insurance benefits verification in writing; (c) MAT policy documentation; (d) accreditation and licensure verification; (e) confirmed prior authorization for specific level of care. Each should be obtained in written form prior to admission. If the clinical situation involves opioid use disorder, confirm explicitly whether Gaïa Paris offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.